JP2019514863A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514863A5 JP2019514863A5 JP2018553226A JP2018553226A JP2019514863A5 JP 2019514863 A5 JP2019514863 A5 JP 2019514863A5 JP 2018553226 A JP2018553226 A JP 2018553226A JP 2018553226 A JP2018553226 A JP 2018553226A JP 2019514863 A5 JP2019514863 A5 JP 2019514863A5
- Authority
- JP
- Japan
- Prior art keywords
- solid form
- acceptable salt
- pharmaceutically acceptable
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 | |
| US62/326,156 | 2016-04-22 | ||
| PCT/EP2017/059511 WO2017182625A1 (en) | 2016-04-22 | 2017-04-21 | Macrocyclic mcl1 inhibitors for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514863A JP2019514863A (ja) | 2019-06-06 |
| JP2019514863A5 true JP2019514863A5 (enExample) | 2020-05-21 |
| JP6894449B2 JP6894449B2 (ja) | 2021-06-30 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553226A Active JP6894449B2 (ja) | 2016-04-22 | 2017-04-21 | 癌を治療するためのマクロ環状ｍｃｌ１阻害剤 |
Country Status (37)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108697729B (zh) | 2016-02-04 | 2023-05-09 | 约翰霍普金斯大学 | 新型GLUT抑制剂rapaglutin及其用途 |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| AU2017214557B2 (en) | 2016-02-04 | 2022-05-19 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| CR20180499A (es) | 2016-04-22 | 2019-01-25 | Astrazeneca Ab | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
| EP3458459B1 (en) | 2016-05-19 | 2022-04-27 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| TWI781996B (zh) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| AU2018317828A1 (en) * | 2017-08-15 | 2020-04-02 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| CR20200124A (es) | 2017-08-15 | 2020-09-28 | Abbvie Inc | Inhibidores macrocíclicos de mcl-1 y métodos de uso |
| AR113887A1 (es) * | 2017-11-17 | 2020-06-24 | Bayer Ag | Derivados de indol macrocíclicos sustituidos con cloro |
| EP3710456B1 (en) | 2017-11-17 | 2022-09-21 | The Broad Institute, Inc. | Macrocyclic indole derivatives |
| EP3710449B1 (en) | 2017-11-17 | 2022-07-06 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| EP3710451A1 (en) * | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Substituted macrocyclic indole derivatives |
| WO2019096914A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| WO2019096907A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| WO2020063792A1 (zh) * | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| TWI749404B (zh) * | 2018-11-22 | 2021-12-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環吲哚 |
| WO2020151738A1 (en) * | 2019-01-23 | 2020-07-30 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
| CA3131939A1 (en) * | 2019-03-08 | 2020-09-17 | Zeno Management, Inc. | Macrocyclic compounds |
| KR20210151183A (ko) | 2019-04-11 | 2021-12-13 | 브리스톨-마이어스 스큅 컴퍼니 | 치료 혈장 농도를 달성하기 위한 무정형 고체 및 가용화된 제제의 증진된 성능 |
| WO2020221272A1 (zh) * | 2019-04-30 | 2020-11-05 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| ES3075769T3 (en) | 2019-05-10 | 2026-08-07 | Janssen Biotech Inc | Macrocyclic chelators and methods of use thereof |
| EP3969457B1 (en) | 2019-05-17 | 2025-08-13 | The Broad Institute Inc. | Methods of preparing macrocyclic indoles |
| AU2020279979A1 (en) | 2019-05-20 | 2021-11-25 | Les Laboratoires Servier | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| MA56505A (fr) | 2019-06-21 | 2022-04-27 | Janssen Pharmaceutica Nv | Inhibiteurs macrocycliques de mcl-1 |
| KR20220034136A (ko) | 2019-07-09 | 2022-03-17 | 얀센 파마슈티카 엔.브이. | Mcl-1 억제제로서의 거대환식 스피로사이클 유도체 |
| WO2021067405A1 (en) * | 2019-10-01 | 2021-04-08 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| CA3157590A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic sulfonyl derivatives as mcl-1 inhibitors |
| US20230021562A1 (en) | 2019-11-21 | 2023-01-26 | Janssen Pharmaceutica Nv | Macrocylic indole derivatives mcl-1 inhibitors |
| AU2020409006A1 (en) * | 2019-12-18 | 2022-06-30 | Zeno Management, Inc. | Macrocyclic compounds |
| CN115151551B (zh) | 2020-02-21 | 2024-10-25 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环吲哚衍生物 |
| CN115335384B (zh) * | 2020-03-30 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种吲哚类大环衍生物的结晶形式及其制备方法 |
| EP4157852A1 (en) | 2020-05-29 | 2023-04-05 | JANSSEN Pharmaceutica NV | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| CN115943147A (zh) | 2020-06-19 | 2023-04-07 | 詹森药业有限公司 | N-连接的大环7-(吡唑-5-基)-吲哚衍生物作为mcl-1抑制剂 |
| CA3181816A1 (en) | 2020-06-19 | 2021-12-23 | Aldo Peschiulli | N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| CA3184877A1 (en) | 2020-07-08 | 2022-01-13 | Benoit Christian Albert Ghislain De Boeck | Macrocyclic ether containing indole derivatives as inhibitors of mcl-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| JP2023553808A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| WO2022129333A1 (en) | 2020-12-17 | 2022-06-23 | Janssen Pharmaceutica Nv | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| CN116848126A (zh) | 2021-02-12 | 2023-10-03 | 詹森药业有限公司 | 大环1,3-桥联的6-氯-7-吡唑-4-基-1h-吲哚-2-羧酸酯和6-氯-7-嘧啶-5-基-1h-吲哚-2-羧酸酯衍生物作为mcl-1抑制剂用于治疗癌症 |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| JP7900421B2 (ja) | 2021-06-11 | 2026-08-04 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ |
| TWI861509B (zh) | 2021-06-11 | 2024-11-11 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| US20240401146A1 (en) | 2021-10-06 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| IL317101A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | Antibody-drug conjugates of anticancer compounds and methods of using them |
| UY40985A (es) | 2023-11-22 | 2025-06-30 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101511074B1 (ko) * | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| MX2009011210A (es) | 2007-04-16 | 2009-10-30 | Abbott Lab | Inhibidores de mcl1 de indol 7-no sustituido. |
| NZ594019A (en) * | 2008-12-22 | 2013-08-30 | Cubist Pharm Inc | Novel antibacterial agents for the treatment of gram positive infections |
| CN102822163B (zh) * | 2009-12-23 | 2016-01-20 | 艾恩伍德医药品股份有限公司 | Crth2调节剂 |
| AU2012257513B2 (en) * | 2011-05-19 | 2017-05-11 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| WO2015031608A1 (en) | 2013-08-28 | 2015-03-05 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| WO2015123230A1 (en) * | 2014-02-12 | 2015-08-20 | Bristol-Myers Squibb Company | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| US10533010B2 (en) | 2014-03-27 | 2020-01-14 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| US9963464B2 (en) * | 2014-04-11 | 2018-05-08 | Bayer Pharma Aktiengesellschaft | Macrocyclic compounds |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| CR20180499A (es) | 2016-04-22 | 2019-01-25 | Astrazeneca Ab | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
-
2017
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en not_active Ceased
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 SM SM20200249T patent/SMT202000249T1/it unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active Active
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es active IP Right Grant
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 MX MX2018012711A patent/MX386103B/es unknown
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200673T1 (hr) | Makrociklički inhibitori mcl1 za liječenje raka | |
| ES2988336T3 (es) | Un agente antineoplásico 1-((4-(4-fluoro-2-metil-1H-indol-5-iloxi)-6-metoxiquinolin-7-iloxi)metil)ciclopropanamina, su forma cristalina y sus sales | |
| JP5366968B2 (ja) | Ｄｎａ中のｇ−四重鎖領域と相互作用するナフタレンジイミド化合物 | |
| JP2010539237A5 (enExample) | ||
| JP2021530565A5 (enExample) | ||
| CR20210626A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| JP2020515574A5 (enExample) | ||
| JP2019528276A5 (enExample) | ||
| JP6457623B2 (ja) | ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用 | |
| JP2020536091A5 (enExample) | ||
| WO2016105528A3 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| ES2911040T3 (es) | Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2) | |
| WO2016160617A3 (en) | Inhibitors of cyclin-dependent kinases | |
| JP2013512956A5 (enExample) | ||
| JP2013512263A5 (enExample) | ||
| AU2009313970A1 (en) | Methods of preparing quinoline derivatives | |
| JP2017509586A5 (enExample) | ||
| JP2014524476A5 (enExample) | ||
| JP2017522276A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2012504628A5 (enExample) | ||
| JP2022511800A5 (enExample) | ||
| JP2018522925A5 (enExample) | ||
| JP2017507175A5 (enExample) | ||
| JP2019534865A5 (enExample) |